Jazz Pharmaceuticals (NASDAQ:JAZZ) Issues FY 2025 Earnings Guidance

Jazz Pharmaceuticals (NASDAQ:JAZZ) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 22.500-24.000 for the period, compared to the consensus EPS estimate of 24.000. The company issued revenue guidance of $4.2 billion-$4.4 billion, compared to the consensus revenue estimate of $4.3 billion. Jazz Pharmaceuticals also updated its FY 2025 guidance to 22.500-24.000 EPS.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded up $2.98 during midday trading on Tuesday, reaching $139.67. The company had a trading volume of 1,271,033 shares, compared to its average volume of 641,912. Jazz Pharmaceuticals has a 1 year low of $99.06 and a 1 year high of $140.52. The business’s 50-day simple moving average is $125.08 and its 200 day simple moving average is $118.24. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock has a market cap of $8.44 billion, a P/E ratio of 19.67, a P/E/G ratio of 1.04 and a beta of 0.56.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, February 25th. The specialty pharmaceutical company reported $5.70 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.83 by ($0.13). Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. On average, analysts forecast that Jazz Pharmaceuticals will post 16.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on JAZZ. Piper Sandler reissued an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Finally, Robert W. Baird boosted their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. One investment analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $180.33.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 2,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $121.17, for a total transaction of $242,340.00. Following the transaction, the chief executive officer now owns 427,025 shares of the company’s stock, valued at approximately $51,742,619.25. The trade was a 0.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 5,053 shares of company stock worth $617,442 in the last ninety days. Insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.